Chinese chip stocks jump as Beijing reportedly warns against Nvidia’s H20
Yvonne Hui, Principal Accounting Officer at Phreesia, Inc. (NASDAQ:PHR), a $1.55 billion healthcare technology company, sold a total of 729 shares of common stock in two separate transactions, netting $19,743. The stock, which InvestingPro analysis indicates is currently undervalued, has experienced a notable 9.56% decline over the past week. On July 15, 2025, Hui sold 307 shares at a weighted average price of $27.2698, for a total of $8371. The prices for these shares ranged from $26.96 to $27.58. Following this, on July 16, 2025, Hui sold 422 shares at a price of $26.95 per share, totaling $11372. Notably, analysts maintain a strong buy consensus on the stock, with price targets ranging from $29 to $35.
The July 15th sale was to cover tax obligations related to the settlement of restricted stock units. The July 16th transaction was executed under a pre-arranged Rule 10b5-1 trading plan established on July 16, 2024. Following these transactions, Hui directly owns 30,281 shares of Phreesia, Inc., which has demonstrated solid revenue growth of 16.29% over the last twelve months. Get more detailed insights and 7 additional ProTips for PHR with an InvestingPro subscription.
In other recent news, Phreesia Inc (NYSE:PHR). reported strong financial results, with its first-quarter earnings surpassing consensus estimates for both revenue and adjusted EBITDA. The company’s adjusted EBITDA increased significantly by 408% to $20.8 million, exceeding the estimated $16 million by about 30%. Revenue guidance remains stable, with anticipated annual growth ranging from 12.4% to 14.8%, slightly lower than the previous fiscal year’s 17.8% growth. Piper Sandler maintained its Overweight rating on Phreesia, raising the adjusted EBITDA forecast for fiscal year 2026 by $4.5 million to a midpoint of $87.5 million. Canaccord Genuity adjusted its price target on Phreesia to $34 from $35, while maintaining a Buy rating, reflecting mixed results in the company’s performance. DA Davidson also reiterated a Buy rating with a price target of $34, citing Phreesia’s expansion in provider scale and product suite as key factors for potential profit growth. Meanwhile, Raymond (NSE:RYMD) James upheld an Outperform rating with a $30 target, emphasizing the company’s financial discipline and strategic investments. JPMorgan reiterated its Overweight rating, noting Phreesia’s revenue diversification strategy and growth potential in its total addressable market. These developments indicate a positive outlook from analysts, who see Phreesia as well-positioned for future growth and profitability.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.